TGFB1 and non-small cell lung carcinoma: The study suggests that the pleiotropic nature of TGF-β signaling, potential drug resistance, and a need for further patient selection beyond PD-L1 status may impact the efficacy of dual-targeted immunotherapies like Bintrafusp Alfa in NSCLC.